Reviving protease inhibitors: new data and more options.
Murphy
Robert L
RL
The Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D000069446:Atazanavir Sulfate; D002219:Carbamates; D002986:Clinical Trials as Topic; D005663:Furans; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000145:classification / Q000627:therapeutic use*; D039682:HIV-Associated Lipodystrophy Syndrome / Q000139:chemically induced; D006801:Humans; D009842:Oligopeptides / Q000627:therapeutic use; D010755:Organophosphates / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D011753:Pyrones / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use
D019380:Anti-HIV Agents; D002219:Carbamates; D005663:Furans; D017320:HIV Protease Inhibitors; D009842:Oligopeptides; D010755:Organophosphates; D011725:Pyridines; D011753:Pyrones; D013449:Sulfonamides; D000069446:Atazanavir Sulfate; C426859:fosamprenavir; C107201:tipranavir